Literature DB >> 12506175

Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor.

Gudrun Schleiermacher1, Martine Peter, Odile Oberlin, Thierry Philip, Hervé Rubie, Françoise Mechinaud, Danièle Sommelet-Olive, Judith Landman-Parker, Danièle Bours, Jean Michon, Olivier Delattre.   

Abstract

PURPOSE: The presence of metastasis is a major prognostic factor in Ewing tumor (ET). The relapse pattern of patients with localized tumors has long indicated that cases with disseminated ET cells escape detection at diagnosis. ET cells are characterized by specific gene fusions that can be detected with high sensitivity and specificity by reverse transcriptase polymerase chain reaction (RT-PCR). PATIENTS AND METHODS: RT-PCR targeting EWS-FLI-1 or EWS-ERG transcripts was used to search for occult tumor cells in peripheral blood (PB) and bone marrow (BM) at diagnosis in 172 patients with ET, and the prognostic significance of this parameter was assessed.
RESULTS: As we suggested previously in a smaller series of patients, RT-PCR positivity of the BM was correlated with a high risk of adverse outcome in the overall study population (P =.007). More interestingly, among patients with otherwise localized tumors, BM micrometastasis also predicted significantly poorer disease-free survival rates (P =.043). The presence of circulating tumor cells (CTC) was more frequently observed in patients with large tumors (P =.006). CTC were associated with a poor outcome among patients with clinically localized disease (P =.045). Patients with clinically localized disease and peripheral occult tumor cells as evidenced by BM and/or PB RT-PCR positivity had axial or proximal tumors and experienced relapses at a systemic rather than at a local level.
CONCLUSION: Patients with localized ET and BM micrometastasis or CTC are comparable to patients with metastases in terms of the localization of the primary tumor, outcome, and relapse pattern.

Entities:  

Mesh:

Year:  2003        PMID: 12506175     DOI: 10.1200/JCO.2003.03.006

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  51 in total

Review 1.  Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.

Authors:  Sandra J Strauss; Tony Ng; Ariadna Mendoza-Naranjo; Jeremy Whelan; Poul H B Sorensen
Journal:  Oncologist       Date:  2010-05-17

2.  Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas.

Authors:  Neerav N Shukla; Juber A Patel; Heather Magnan; Ahmet Zehir; Daoqi You; Jiabin Tang; Fanli Meng; Aliaksandra Samoila; Emily K Slotkin; Srikanth R Ambati; Alexander J Chou; Leonard H Wexler; Paul A Meyers; Ellinor I Peerschke; Agnes Viale; Michael F Berger; Marc Ladanyi
Journal:  JCO Precis Oncol       Date:  2017-05-23

3.  Paley's multiplier method does not accurately predict adult height in children with bone sarcoma.

Authors:  Magdalena Maria Gilg; Christine Wibmer; Dimosthenis Andreou; Alexander Avian; Petra Sovinz; Werner Maurer-Ertl; Per-Ulf Tunn; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2014-04-29       Impact factor: 4.176

Review 4.  Circulating tumor cells in sarcomas: a brief review.

Authors:  Le Chang; Greg Asatrian; Sarah M Dry; Aaron W James
Journal:  Med Oncol       Date:  2014-12-10       Impact factor: 3.064

Review 5.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 6.  Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.

Authors:  Beatrice M Seddon; Jeremy S Whelan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 7.  Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment.

Authors:  Hervé Brisse; Liliane Ollivier; Véronique Edeline; Hélène Pacquement; Jean Michon; Christophe Glorion; Sylvia Neuenschwander
Journal:  Pediatr Radiol       Date:  2004-04-22

8.  Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow.

Authors:  Steven G Dubois; C Lorrie Epling; Juli Teague; Katherine K Matthay; Elizabeth Sinclair
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

9.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Authors:  K Beiske; S A Burchill; I Y Cheung; E Hiyama; R C Seeger; S L Cohn; A D J Pearson; K K Matthay
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

Review 10.  Molecular pathology of sarcomas: concepts and clinical implications.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-09-29       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.